Los Angeles, California, October 5, 2022 – Kataoka Corporation (Kyoto, Japan) and Kataoka-SS America Corporation (Carson, CA) have developed the CPD-017, a cell processing platform that uses cutting edge laser and AI technology to purify adherent iPSC cultures. [Read more…]
Cord Blood Banking in India, a Country That is Home to 1.8 Billion
ReeLabs is an important cord blood banking brand within India. Cord blood banking in this region is of historic importance, because India has an astounding population of 1.4 billion. Representing 18% of the global population, nearly one-in-five people lives in India, placing it head-to-head with China as the world’s most populous country. India’s population growth is fueled by a birth rate (19 births/1,000 population) that substantially exceeds its death rate (7.3 deaths/1,000 population).
If you’re involved with cord blood banking, then you need to pay attention to this enormous consumer market.
In this interview with Dr. Abhijit Bopardikar, Director of ReeLabs, he explains the rise of cord blood banking within India and discusses the importance of pairing stem cell therapy and research applications with stem cell storage services.
[Read more…]
An Expert’s Perspective on Accelerated Pathways for Cell Therapy Approvals
Over the past few years, the regulatory landscape for cell therapy development has grown increasingly complex. There are now accelerated pathways for advanced therapy medicinal products (ATMPs) in several countries worldwide, including the U.S., Japan, and South Korea. While the possibility for accelerated commercialization has resulted from these changes, substantial complexity has also been introduced, making it a more elaborate process to move cell therapy products from “bench to bedside.”
In the interview with Yaron Ramati, Director of Regulatory Affairs at Pluristem Therapeutics, we get an expert’s perspective on how the regulatory environment has changed and new opportunities that exist for bringing cell therapy products through the clinical trial process and into the global marketplace. [Read more…]
Defence Therapeutics Reports Reprogrammed MSC Vaccine Cures 80% of Animals with Lymphoma Cancer
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia, September 21, 2022 – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence’s novel vaccine candidate triggers a potent anti-tumoral response capable of curing animals with pre-established lymphoma. [Read more…]
CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop “off-the-shelf” CAR-iMAC cell therapy
Sept. 5, 2022, China, HANGZHOU — CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy. [Read more…]
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 201
- Next Page »